More RFID Journal Sites: RFID Journal Espanol RFID Journal Brasil RFID Journal Events RFID Journal Awards
RFID NEWS
Text size:
T
T
T
Six U.K. Drugmakers Pilot RFID
Merck, Novartis and other companies are running a trial that tags individual items to detect dispensing errors and counterfeit drugs before they reach patients.
By Jonathan Collins
Nov. 19, 2004—A pharmaceutical RFID and bar code pilot underway in the U.K. aims to detect dispensing errors and counterfeit drugs before they reach patients but without tracking items as they move through the pharmaceutical supply chain.
The "authentication at the point of dispensing" pilot has been organized by start-up Aegate and brings together six U.K. pharmaceutical companies—including Merck Generics U.K., Merck Pharmaceuticals, Novartis, Schering Health Care and Solvay—and 50 dispensing outlets, which include hospitals and small pharmacies across England. Aegate says its trial is targeted only at providing pharmacists and doctors with information in a pragmatic way to authenticate products at the point of dispensing.
"There has been a lot of interest in RFID for track and trace in the pharmaceutical supply chain focused on increasing efficiency, but the focus of this pilot is patient safety," says Ian Rhodes, CEO at Aegate, which is based in Cambridge U.K.
Aegate believes that trying to implement track and trace in the pharmaceutical supply chain would be an unnecessarily complicated and unwieldy solution that would hamper much of the business of supplying drugs across Europe. "When these highly regulated products leave the front gate of the manufacturer, they go into a very complex supply chain. These are high-value, easy-to-transport items with a long shelf life, so they can become commodities traded up to 30 times before reaching the dispensing pharmacist. We want to find a way to protect patients without standing in the way of that free market," says Rhodes.
During the three-month pilot, which started in October, the pharmaceutical companies involved in the pilot will tag between 20,000 to 30,000 from a total of 12 different branded and non-branded pharmaceutical products. The RFID tags will be placed on the inside of the cardboard packaging of items in a range of formats, including blister packs, bottles, canisters and aerosols.
The pilot is using read-only 13.56 MHz tags from Rafsec that conform to the ISO15693. RFID tags are being used along with a range of bar code technologies. According to Aegate, while RFID will be one way of authenticating individual items with a unique ID number, EAN 128, Datamatrix 2D and RSS 14 bar codes will also be used in the trial to label an additional quantity of items. Aegate maintains that some pharmaceutical companies may opt to not trial RFID for some of their products—such generic drugs—because the higher cost of RFID tags could have too great an impact on the profit margins on those products.
"We are using a range of mass-serialization [numbering] techniques in the pilot," says Rhodes, adding that RFID can increase the level of counterfeit protection by pushing up the cost of counterfeiting. According to Aegate, a counterfeiter can easily and cheaply copy a printed bar code. Copying holograms is also relatively cheap and easy; some holograms have been copied within three months of being put on a pack. An RFID tag diminishes an item's attractiveness to a counterfeiter because the cost of creating a counterfeit copy of an RFID tag is higher and harder. For many items, however, the technology will be too expensive for some pharmaceutical companies to deploy. Nonetheless, among the technologies being used in the pilot, RFID uniquely enables pharmacists to read an ID number of products sealed inside a carton without needing to remove the contents of that carton. This makes its easier and quicker for pharmacists to inventory and dispense items.
Nov. 19, 2004—A pharmaceutical RFID and bar code pilot underway in the U.K. aims to detect dispensing errors and counterfeit drugs before they reach patients but without tracking items as they move through the pharmaceutical supply chain.
The "authentication at the point of dispensing" pilot has been organized by start-up Aegate and brings together six U.K. pharmaceutical companies—including Merck Generics U.K., Merck Pharmaceuticals, Novartis, Schering Health Care and Solvay—and 50 dispensing outlets, which include hospitals and small pharmacies across England. Aegate says its trial is targeted only at providing pharmacists and doctors with information in a pragmatic way to authenticate products at the point of dispensing.
|
| Aegate's Ian Rhodes |
Aegate believes that trying to implement track and trace in the pharmaceutical supply chain would be an unnecessarily complicated and unwieldy solution that would hamper much of the business of supplying drugs across Europe. "When these highly regulated products leave the front gate of the manufacturer, they go into a very complex supply chain. These are high-value, easy-to-transport items with a long shelf life, so they can become commodities traded up to 30 times before reaching the dispensing pharmacist. We want to find a way to protect patients without standing in the way of that free market," says Rhodes.
During the three-month pilot, which started in October, the pharmaceutical companies involved in the pilot will tag between 20,000 to 30,000 from a total of 12 different branded and non-branded pharmaceutical products. The RFID tags will be placed on the inside of the cardboard packaging of items in a range of formats, including blister packs, bottles, canisters and aerosols.
The pilot is using read-only 13.56 MHz tags from Rafsec that conform to the ISO15693. RFID tags are being used along with a range of bar code technologies. According to Aegate, while RFID will be one way of authenticating individual items with a unique ID number, EAN 128, Datamatrix 2D and RSS 14 bar codes will also be used in the trial to label an additional quantity of items. Aegate maintains that some pharmaceutical companies may opt to not trial RFID for some of their products—such generic drugs—because the higher cost of RFID tags could have too great an impact on the profit margins on those products.
"We are using a range of mass-serialization [numbering] techniques in the pilot," says Rhodes, adding that RFID can increase the level of counterfeit protection by pushing up the cost of counterfeiting. According to Aegate, a counterfeiter can easily and cheaply copy a printed bar code. Copying holograms is also relatively cheap and easy; some holograms have been copied within three months of being put on a pack. An RFID tag diminishes an item's attractiveness to a counterfeiter because the cost of creating a counterfeit copy of an RFID tag is higher and harder. For many items, however, the technology will be too expensive for some pharmaceutical companies to deploy. Nonetheless, among the technologies being used in the pilot, RFID uniquely enables pharmacists to read an ID number of products sealed inside a carton without needing to remove the contents of that carton. This makes its easier and quicker for pharmacists to inventory and dispense items.
